Osteoporosis affects millions of people worldwide, weakening bones and increasing the risk of fractures. Now, researchers have identified the AXL receptor tyrosine kinase (Axl) as a key molecule that limits the activity of bone-forming cells. Blocking Axl with a small-molecule inhibitor increased bone formation and bone mass in mice while revealing how the receptor controls bone development. These findings could support the development of more accessible treatments for osteoporosis and other bone diseases.

New genetic risk factors have been identified for fibromyalgia syndrome.

The landmark study, which involved scientists at King’s College London, published in Nature Medicine, highlights how the nervous system plays an important role in the development of the disorder.